Senior Manager of Scientific Business Development at Deep Longevity, Russia
Miсhelle Keller is heading a team of scientific business developers at Deep Longevity, an artificial intelligence (AI) company developing and utilizing deep learning systems for aging and longevity research and a pioneer in deep biomarkers of aging. As a young aspiring scientist in the field of bioinformatics, Michelle was always fascinated by the idea of increasing human lifespan beyond limits. She started her career as a research scientist at Insilico Medicine, a leader in the field of next-generation AI solutions for drug discovery and development. In 2020, when Insilico announced Deep Longevity as a spin-off focusing on longevity extension, Michelle chose to focus on biomarkers of aging and joined the newly-founded company as a research scientist.
At Deep Longevity she invented and implemented several critical applications of AI-based biomarkers of aging in clinical practice and developed the research and commercial relationships with the leading longevity clinics including Human Longevity, Inc, Hooke London, Epigenetic House, Life Clinic Hong Kong, Boulder Longevity, and many others.
Deep Longevity operates as a flat organization with matrix leadership and Michelle Keller helped build a new branch of the company—scientific business development. As the manager of scientific business development she works with the clinics and insurance companies to conduct cutting-edge research to develop an integrated longevity ecosystem - make life insurance companies and clinics work together to increase customer longevity. Michelle works with her team to find new reliable ways to translate scientific theory into real-world practice. Every project and product under Michelle’s supervision is yet another step towards implementing LaaS (Longevity as a Service) solutions.